Ewing sarcoma breakpoint region 1 protein (EWSR1)

Ewing sarcoma breakpoint region 1 protein (EWSR1) is a ubiquitously expressed, nuclear-localized RNA-binding protein of the TET family, essential for transcriptional regulation and mRNA splicing, with additional roles in DNA damage response, cell cycle progression, and neuron differentiation[1][3][4][5][6]. EWSR1's major clinical importance arises from its frequent involvement in chromosomal translocations with transcription factors (especially FLI1), producing chimeric oncoproteins such as EWSR1-FLI1 that act as aberrant transcription factors driving Ewing sarcoma and other cancers[1][2][4]. These fusion proteins lose the RNA-binding function and instead acquire potent, dysregulated transcriptional activity, altering cell proliferation, differentiation, and survival. EWSR1 gene fusions serve as crucial diagnostic and therapeutic targets in oncology, with ongoing research into molecular inhibitors and nucleic acid-based therapies. Direct pharmacological targeting is challenging due to the protein’s structure and native cellular functions[1][2][4][5][6]. Detection of EWSR1 fusions is a key biomarker in Ewing sarcoma and other fusion-associated solid tumors[1][6].

Other names

RNA-binding protein EWSEWSEWS oncogeneEWS-FLI1EWSR1-FLI1Ewing sarcoma breakpoint region 1Ewing sarcoma proteinEwings sarcoma EWS-Fli1 (type 1) oncogene

- Inhibition of protein-protein interaction (e.g., EWS-FLI1 and RHA by YK-4-279)[1] - Inhibition of IGF1 signaling pathway (by targeting IGF1 receptor)[1] - Inhibition of MET signaling (by targeting MET in EWSR1-CREB1 fusion)[1] - Targeted gene or transcript knockdown using RNA interference, antisense oligonucleotides, or CRISPR/Cas9[2] - Disruption of aberrant transcriptional regulation driven by fusion proteins